Leigh M Spicer, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 899 Island Park Dr, Ste. 200, Daniel Island, SC 29492 Phone: 843-856-6402 Fax: 843-216-5068 |
Dr. Jessica Hund, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 964 Island Park Drive, Ste 101, Daniel Island, SC 29403 Phone: 843-876-7975 |
John Gardner Inman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 880 Island Park Dr Unit 200, Daniel Island, SC 29492 Phone: 843-856-1771 Fax: 843-856-8788 |
Lucy Green Davis, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 899 Island Park Dr, Ste 200, Daniel Island, SC 29492 Phone: 843-856-6402 Fax: 843-216-5068 |
Dr. Melissa Hodge Hunter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 245 Seven Farms Dr Ste 110, Daniel Island, SC 29492 Phone: 843-856-1771 Fax: 843-856-8788 |
Edward J Giove, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 297 Seven Farms Dr Ste 202, Daniel Island, SC 29492 Phone: 843-936-4470 Fax: 843-256-6877 |
Dr. Kimberly Shelley Jackson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 864 Island Park Dr Ste 101, Daniel Island, SC 29492 Phone: 843-876-7975 |
News Archive
Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing gene to those of the small molecules, said a Baylor College of Medicine researcher in a report that appears in the current online issue of the journal PLoS One (Public Library of Science ONE).
A team of researchers from Australia and France have uncovered new insights into how to prolong the lifespan of the body's disease-fighting natural killer (NK) cells.
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs like aspirin may lessen the adverse effects of air pollution exposure on lung function.
Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in August 2009, the companies are leveraging Silence's proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate functional delivery of RNA interference (RNAi) therapeutics to specific disease targets in the body.
› Verified 3 days ago